-
21.发明公开
公开(公告)号：EP2150254A4
公开(公告)日：2010-11-10
申请号：EP08747020
申请日：2008-04-28
发明人： LOCKHART DAVID , WUSTMAN BRANDON
CPC分类号： A61K31/445 , A61K31/45
-
公开(公告)号：EP2145187A4
公开(公告)日：2010-10-27
申请号：EP08745665
申请日：2008-04-11
发明人： BENJAMIN ELFRIDA
IPC分类号： G01N33/52
CPC分类号： G01N33/5308 , G01N2400/48 , G01N2800/042
-
公开(公告)号：EP2145187A1
公开(公告)日：2010-01-20
申请号：EP08745665.3
申请日：2008-04-11
发明人： BENJAMIN, Elfrida
IPC分类号： G01N33/551 , C12Q1/70
CPC分类号： G01N33/5308 , G01N2400/48 , G01N2800/042
摘要： Provided is a method of detecting the presence and quantitating the amount of glycogen from a biological sample. This method employs PAS staining with detection in the infrared range.
-
公开(公告)号：EP2027137A1
公开(公告)日：2009-02-25
申请号：EP06772888.1
申请日：2006-06-09
IPC分类号： C07H5/04 , C07D211/40
CPC分类号： C07H5/04 , C07D211/40 , C07D211/46
摘要： Novel processes for the purification of an imino or amino sugar, such as D-1-deoxygalactonojirimycin (DGJ). Particularly, there are described processes for the purification of multi-kilogram scale sugars using hydrochloric acid.
-
25.发明公开GLUCOIMIDAZOLE AND POLYHYDROXYCYCLOHEXENYL AMINE DERIVATIVES TO TREAT GAUCHER DISEASE 审中-公开GLUCOIMIDAZOL和POLYHYDROXYCYCLOHEXENYL胺衍生物的戈谢病的治疗
公开(公告)号：EP1682134A4
公开(公告)日：2008-10-15
申请号：EP04810771
申请日：2004-11-12
发明人： FAN JIAN-QIANG , ZHU XIAOXIANG , SHETH KAMLESH
IPC分类号： A61K31/437 , A61K20060101 , A61K31/445 , A61K31/454 , A61K31/4745 , A61K31/50 , A61K31/501 , A61K48/00 , A61P43/00 , C07D211/40 , C07D471/02 , C07D471/04
CPC分类号： C07D487/04
-
26.发明授权
公开(公告)号：EP3914247B1
公开(公告)日：2024-11-13
申请号：EP20708283.5
申请日：2020-01-22
发明人： SKUBAN, Nina , LAGAST, Hjalmar
IPC分类号： A61K31/445 , A61P9/00 , A61P25/00
-
公开(公告)号：EP4370120A1
公开(公告)日：2024-05-22
申请号：EP22761857.6
申请日：2022-07-12
发明人： JOHNSON, Franklin
IPC分类号： A61K31/445 , A61P43/00
CPC分类号： A61K31/445 , A61P43/00
-
公开(公告)号：EP4324522A3
公开(公告)日：2024-05-22
申请号：EP23219949.7
申请日：2018-05-30
发明人： Castelli, Jeff
IPC分类号： A61K31/445 , A61P13/12
CPC分类号： A61K31/445 , A61P13/12 , C12Y302/01022
摘要： Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing α-galactosidase A activity in the patient.
-
29.发明公开
公开(公告)号：EP4363437A1
公开(公告)日：2024-05-08
申请号：EP22768557.5
申请日：2022-07-01
发明人： EISENACH, Helen , TUSKE, Steven
CPC分类号： C07K7/083 , C07K14/72 , C07K2319/7420130101 , C07K2319/0620130101 , C12Y302/0102
-
公开(公告)号：EP4324521A3
公开(公告)日：2024-04-24
申请号：EP23219937.2
申请日：2017-07-19
发明人： Castelli, Jeff
IPC分类号： A61K31/445 , A61P9/00 , A61P3/00 , A61P13/12
CPC分类号： A61K31/445 , A61K31/45 , A61K31/7008 , A61P13/12 , A61P3/00 , A61P39/02 , A61P43/00 , A61P9/00
摘要： Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-naïve Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.
-
-
-
-
-
-
-
-
-
搜索结果
170 条记录 (耗时 0.018 秒)
